Biography

Mr. Hagler joined NovaBridge in April 2026. He is a biotechnology commercial executive with more than 25 years of experience building, scaling, and transforming biopharmaceutical and specialty pharmaceutical businesses. He brings distinctive expertise in driving accelerated growth, commercial readiness, and organizational development for companies in oncology, immunology, ophthalmology, and rare disease markets.

Before joining NovaBridge, Mr. Hagler served as Chief Commercial Officer for Sun Pharmaceuticals Industries Limited (Sun), where he led a $1B+ portfolio and organization of 600+ professionals, with accountability for strategy, performance and growth. Under his leadership, Sun’s U.S. Oncology business scaled from inception to profitability. In addition, Mr. Hagler led the transformation of the Ophthalmology division, establishing robust operational standards and delivering positive cash flow. He also executed strategic acquisitions that added value to the company’s pipeline and expanded its market reach.

Earlier in his career, Mr. Hagler held senior leadership roles at Ipsen S.A., Sanofi, Novartis AG, and Abraxis BioScience, Inc., where he shaped the global launch and lifecycle strategies for oncology therapies including Afinitor® and Abraxane®, driving meaningful clinical adoption and long-term commercial value. Mr. Hagler’s experience spans IND-to-commercialization drug development, pipeline prioritization, business development, pricing and market access strategy, cross-functional organizational leadership, and field model optimization for high-science markets.

Mr. Hagler is a named inventor on three U.S. design patents for medical technology innovations. He holds an MBA in Corporate Finance from Johns Hopkins University and is a graduate of the United States Naval Academy.